- Home
- MURA vs KUKE Comparison
MURA vs KUKE Comparison
Compare MURA & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- KUKE
- Stock Information
- Founded
- MURA 2013
- KUKE 2002
- Country
- MURA Ireland
- KUKE China
- Employees
- MURA N/A
- KUKE N/A
- Industry
- MURA
- KUKE Other Consumer Services
- Sector
- MURA
- KUKE Real Estate
- Exchange
- MURA Nasdaq
- KUKE Nasdaq
- Market Cap
- MURA 36.0M
- KUKE 42.0M
- IPO Year
- MURA N/A
- KUKE 2021
- Fundamental
- Price
- MURA $2.08
- KUKE N/A
- Analyst Decision
- MURA Buy
- KUKE
- Analyst Count
- MURA 2
- KUKE 0
- Target Price
- MURA $6.00
- KUKE N/A
- AVG Volume (30 Days)
- MURA 157.1K
- KUKE 934.4K
- Earning Date
- MURA 11-12-2025
- KUKE 10-21-2025
- Dividend Yield
- MURA N/A
- KUKE N/A
- EPS Growth
- MURA N/A
- KUKE N/A
- EPS
- MURA N/A
- KUKE N/A
- Revenue
- MURA N/A
- KUKE $9,442,397.00
- Revenue This Year
- MURA N/A
- KUKE N/A
- Revenue Next Year
- MURA N/A
- KUKE N/A
- P/E Ratio
- MURA N/A
- KUKE N/A
- Revenue Growth
- MURA N/A
- KUKE N/A
- 52 Week Low
- MURA $0.95
- KUKE $0.52
- 52 Week High
- MURA $4.74
- KUKE $10.00
- Technical
- Relative Strength Index (RSI)
- MURA 53.11
- KUKE 21.89
- Support Level
- MURA $2.06
- KUKE $0.52
- Resistance Level
- MURA $2.12
- KUKE $0.62
- Average True Range (ATR)
- MURA 0.02
- KUKE 0.08
- MACD
- MURA -0.00
- KUKE -0.03
- Stochastic Oscillator
- MURA 41.67
- KUKE 9.01
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.